Prostaglandins and the regulation of tumor growth

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 21, Issue 2, 2002, Pages 93-101

  Bishop Bailey, David ^a   Calatayud, Sara ^a   Warner, Timothy D ^a   Hla, Timothy ^b   Mitchell, Jane A ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cancer; Colony stimulating factors; Cyclooxygenase; Peroxisome proliferator activated receptor; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; COLONY STIMULATING FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN H2; PROSTAGLANDIN J2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARACHIDONIC ACID METABOLISM; CANCER; CONFERENCE PAPER; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GROWTH REGULATION; HUMAN; IMMUNE RESPONSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALIA;

EID: 0036081683     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v21.i2.20     Document Type: Conference Paper

References (59)

1. Distribution of COX-1 and COX-2 in normal and inflamed tissues
2. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
3. Restoration of prostacyclin synthase in vascular smooth muscle after aspirin treatment: Regulation by epidermal growth factor
4. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
5. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
6. Human cyclooxygenase-2 cDNA
7. Cyclo-oxygenase-2 in vascular smooth muscle
8. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy
9. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
10. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
11. Cyclooxygenase-1 and -2 isoenzymes
12. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
13. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
14. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids
15. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist
16. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain
17. Multiple controls in inflammation. Extracellular and intracellular phospholipase A2, inducible and constitutive cyclooxygenase, and inducible nitric oxide synthase
18. Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: Evidence for a "two-component" model
19. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: Consequences for nonsteroidal antiinflammatory drug efficacy
20. Prostanoid receptor heterogeneity through alternative mRNA splicing
21. 2 is a ligand for the adipocyte determination factor PPARγ
22. 2 metabolite binds peroxisone proliferator-activated receptor γ and promotes adipocyte differentiation
23. Molecular regulation of adipogenesis
24. Peroxisome proliferator-activated receptors in the cardiovascular system
25. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
26. 2
27. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
28. 15-Deoxy-Delta(12,14) PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells
29. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma
30. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
31. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
32. Aspirin and the risk of colorectal cancer in women
33. Colorectal cancer and nonsteroidal anti-inflammatory drugs
34. Cyclooxygenase in biology and disease
35. Aspirin use and potential mechanisms for colorectal cancer prevention
36. Cyclooxygenase-2 expression in human esophageal carcinoma
37. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
38. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
39. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
40. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
41. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis
42. Significant roles of inducible cyclo-oxygenase (COX)-2 in angiogenesis in rat sponge implants
43. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
44. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
45. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death
46. Biosynthesis of prostaglandins and hydroxy fatty acids in primary squamous carcinomas of head and neck in humans
47. Prostaglandin and thromboxane synthesis by human intracranial tumors
48. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients
49. Granulocyte colony stimulating factors: How different are they? How to make a decision?
50. Cancer immunotherapy in clinical oncology
51. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
52. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
53. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells
54. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity
55. Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines
56. Cyclo-oxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: Role of cAMP
57. Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: Differential regulation by COX-2
58. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy
59. Endogneous GM-CSF modulates COX-2 activity in human venous smooth muscle cells